Figure 4 shows that T2DM-stroke mice exhibited significantly increased liver steatosis measured by Oil red O staining, increased ballooning degeneration of hepatocytes, increased fibrosis measured by PicroSirius Red, increased serum ALT activity, and higher NAS compared to T2DM-Sham mice, with super-additive effect observed on hepatocyte ballooning, fibrosis, NAS and ALT. CD133 + Exo treatment of T2DM-stroke mice significantly decreased liver steatosis, hepatocellular ballooning, fibrosis, serum ALT activity, and NAS compared to T2DM-stroke mice at 28 days after stroke (Figures 4A-H). Here, PROM1 is linked to Stroke.